- Home
- / Immune Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Immune Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2023-12-20
Market Capitalization
$7.8 M
2023-12-20
Revenue
$113.5 K
FY, 2018
CreditSafe Score
?
Score changed on Jul 23, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.2K | 3.5K | 113.5K | ||||||||
| Revenue growth, % | -78.6% | ||||||||||
| Cost of goods sold | 47.7K | ||||||||||
| Gross profit | 65.8K | ||||||||||
| Gross profit margin, % | 58.0% | ||||||||||
| General and administrative expense | 71.1M | 4.1M | 2.7M | 3.9M | 2.8M | 3.2M | 2.4M | 760.1K | 585.5K | 1.1M | 957.1K |
| Operating expense total | 93.1M | 16.4M | 3.7M | 4.3M | 3.2M | 4.2M | 2.7M | 886.4K | 1.2M | 1.4M | |
| Depreciation and amortization | 2.9M | 2.9M | 594.8K | 1.6K | 826.0 | 1.7K | 2.1K | 639.0 | |||
| EBIT | (96.0M) | (45.3M) | (15.8M) | (14.3M) | (5.9M) | (4.1M) | (2.8M) | (887.0K) | (738.2K) | (1.2M) | (1.5M) |
| EBIT margin, % | -97566.8% | -412125.0% | -3599.0% | ||||||||
| Investment income | (376.2K) | ||||||||||
| Interest expense | 10.1M | 4.7M | 1.1M | 5.5M | 2.0M | 4.5M | 120.4K | 168.3K | |||
| Net Income | (106.1M) | (49.9M) | (16.9M) | (19.8M) | (7.9M) | (8.6M) | (3.4M) | 1.6M | 3.6M | (3.5M) | (2.4M) |
| EPS | (0.1) | 0.0 |